# PALMITOYL TRIPEPTIDE-1 (palmitoyl-tripeptide-1) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/palmitoyl-tripeptide-1
- **Standard INCI**: `PALMITOYL TRIPEPTIDE-1`
- **KR MFDS Standard Name**: `팔미토일트라이펩타이드-1`
- **CAS No.**: `147732-56-7`
- **EC / EINECS No.**: `N/A`
- **Origin**: `peptide`
- **Functions**: 피부컨디셔닝제
- **Molecular Formula / MW**: `C30H54N6O5` (578.8 g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 팔미토일트라이펩타이드-1 |
| KR (Former Names) | 팔미토일트리펩타이드-1 |
| EU (CosIng 1223/2009) | PALMITOYL TRIPEPTIDE-1 |
| US (PCPC / MoCRA INCI) | PALMITOYL TRIPEPTIDE-1 |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | 棕榈酰三肽-1 |
| JP (JCIA / MHLW QD) | PALMITOYL TRIPEPTIDE-1  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `none`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `8747`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- **cn_iecic_max** (leave_on): ≤ 0.2% — NMPA IECIC (2025) Entry 08941 (2025)
- **cn_iecic_max** (rinse_off): ≤ 0.1% — NMPA IECIC (2025) Entry 08941 (2025)

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 4.5 – 7.5
- **Max Process Temp**: ≤ 50°C
- **Synergy Pairings**: PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE
- **Incompatibilities**: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: PALMITOYL TRIPEPTIDE-1 | CAS No.: 147732-56-7 | EC No.: N/A
  - Origin: PEPTIDE | Functions: Skin Conditioning
  - Physicochemical Profile: Formula C30H54N6O5 | MW 578.8 g/mol | LogP 2.8 | Ionic Nature: amphoteric | PubChem CID 9862849
  - Official Regional Label Names: US [PALMITOYL TRIPEPTIDE-1] · EU [PALMITOYL TRIPEPTIDE-1] · CN [棕榈酰三肽-1] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1 Classified under origin 'peptide', it acts within the cosmetic vehicle or stratum corneum to deliver  performance and structural formulation stability.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 8747 (棕榈酰三肽-1))
  - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment).
  - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 0.2% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 0.1%
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [emulsion_cream] Typical range: 0.001 ~ 0.15% (Median 0.01%, Ref: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment) — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Cool-down Phase (< 45°C)
  - Optimal pH Range: pH 4.5 ~ 7.5 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM
  - Incompatibility / Caution: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C
  - Synergy Pairings: PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE | Reference Trade Names: Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7), Biopeptide CL™
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - PMID 41527525 (2026, J Cosmet Dermatol): Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism

## 6. Linked PubMed Literature
- [PMID: 41527525] Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism — *J Cosmet Dermatol* (2026)